首页>
外国专利>
PHARMACEUTICAL FORMULATION CONTAINING AN INSULIN DERIVATIVE MODIFIED WITH A BASE, WITH AN ISOELECTRIC POINT BETWEEN 5.8 - 8.5, AND WITH A ZINC ION CONTENT OF FROM 2MUG - 200MUG OF ZINC/IU
PHARMACEUTICAL FORMULATION CONTAINING AN INSULIN DERIVATIVE MODIFIED WITH A BASE, WITH AN ISOELECTRIC POINT BETWEEN 5.8 - 8.5, AND WITH A ZINC ION CONTENT OF FROM 2MUG - 200MUG OF ZINC/IU
Pharmaceutical formulations for the treatment of diabetes mellitus are disclosed, wherein the pharmaceutical formulations contain at least one insulin derivative modified with a base in position B31 of the insulin B chain and having an isoelectric point between 5.8 and 8.5 and/or at least one of its physiologically tolerated salts in a pharmaceutically acceptable excipient and a relatively high zinc ion content in the range from above 1 mu g to about 200 mu g of zinc/IU. The preferred insulin derivative modified with a base for this pharmaceutical formulation is human insulin-B31-Arg-OH and human insulin-B31-Arg-B32-Arg-OH. The formulation is used for the treatment of diabetes mellitus; it has a particularly favorable action profile.
展开▼